ClinicalTrials.gg
RecruitingNCT07709598Updated Jul 16, 2026

Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery

A Phase 2/3 interventional study of HL-1186 and HL-1186 placebo in Postoperative Pain, sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.

Planned enrollment
20th of 205
330 · median 132
Started
2026
with 34 others
Phase 2/3
5 of 248
3 open now
Primary completion
2026-10
later than 43 of 79 live
Registered
238th of 248
by date

Among the 248 studies in Pain, Postoperative with a site in China, this one is the 20th largest by planned enrollment of the 205 interventional ones that give a count, is one of 35 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 43 of the 79 other live ones, and was the 238th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

72 more — sign in →

All 78 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

This clinical trial is a multiple-center, randomized, double-blind, placebo- and active-controlled parallel-group Phase II/III clinical trial, to evaluate the efficacy and safety of HL-1186 Tablets for Postoperative Analgesia in Abdominal Surgery.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ age ≤ 75 years old, gender is not limited.
  2. 18 kg/m2 ≤ (BMI) ≤ 30kg/m2.
  3. Scheduled to undergo abdominal surgery under general anesthesia, with expected moderate-to-severe postoperative pain intensity.
  4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.
  5. After surgery completion, the participant is judged by the investigator to be awake and has a resting NRS score ≥ 4.

Exclusion criteria

Exclusion Criteria:

  1. Previous surgery on the same site that may affect pain perception at the surgical site.
  2. Paresthesia or other pain that may affect postoperative pain evaluation or scale assessment.
  3. Neuropsychological disorders that may affect postoperative pain evaluation or scale assessment.
  4. Unstable angina, myocardial infarction, severe arrhythmia, cardiac function class ≥ III, or recurrent asthma attacks, etc., deemed unsuitable for inclusion by the investigator.
  5. Poorly controlled hypertension.
  6. Sleep apnea syndrome, or the presence of a difficult airway as assessed by the investigator.
  7. Known allergy to any component of the drug(s), to perioperative (from induction of anesthesia to completion of surgery) anesthetic/analgesic/antiemetic drugs, or a history of allergy to ≥ 3 substances.
  8. Positive for (HIV) antibody; positive for Treponema pallidum antibody and positive toluidine red unheated serum test (TRUST); positive for surface antigen (HBsAg) with detectable HBV-DNA; or positive for virus (HCV) antibody.
  9. Women who are pregnant or breastfeeding (within 1 year after delivery).
  10. Participation in another drug or medical device trial within 1 month before screening, or currently participating in another clinical trial receiving investigational intervention.
  11. Any other condition considered unsuitable for participation by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    HL-1186 High-Dose Group

    Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours

    Drug: HL-1186 · Drug: Oxycodone-Acetaminophen Matching Placebo

  • Experimental
    HL-1186 Low-Dose Group

    Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours

    Drug: HL-1186 · Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen Matching Placebo

  • Active comparator
    Oxycodone-Acetaminophen Group

    Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours

    Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen

  • Placebo comparator
    Placebo Group

    Participants will be randomized to either the HL-1186 groups, placebo group or active-comparator group, and administer study drug every 6 hours

    Drug: HL-1186 placebo · Drug: Oxycodone-Acetaminophen Matching Placebo

Interventions

  • HL-1186 tablet for oral administration.

  • DrugHL-1186 placebo

    HL-1186 placebo tablet for oral administration.

  • Oxycodone-Acetaminophen for oral adminstration.

  • DrugOxycodone-Acetaminophen Matching Placebo

    Oxycodone-Acetaminophen Matching Placebo for oral adminstration.

06

What researchers measure

Primary outcomes

  1. SPID48

    SPID48: Time-weighted Sum of the Pain Intensity Difference (SPID) as recorded on an NRS (Numeric Rating Scale, 0 =no pain to 10 =worst possible pain) at rest 0 to 48 hours after the first dose of study drug. The score range was -480 (worst score) to 480 (best score).

    Time frame: 0 to 48 hours

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Time frame: 0-9 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.

Of 52 phase 2/3 interventional studies under Pain, Postoperative, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Jul 16, 2026
StartActual
May 11, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709598
Lead sponsor
Shanghai Huilun Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
May 11, 2026
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 16, 2026

Study contacts

Renhai Yang
Contact
clinical_trial@hllife.com.cn
021-64311017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HL-1186

Start the discussion